Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations
Identifieur interne : 004E25 ( Main/Merge ); précédent : 004E24; suivant : 004E26Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations
Auteurs : Katherine L. Widnell [États-Unis] ; Cynthia Comella [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-05.
English descriptors
- KwdEn :
- Apomorphine (pharmacology), Apomorphine (therapeutic use), Benzophenones (pharmacology), Benzophenones (therapeutic use), COMT inhibition, Catechol O-Methyltransferase Inhibitors, Catechols (pharmacology), Catechols (therapeutic use), Dopamine Agonists (pharmacology), Dopamine Agonists (therapeutic use), Ergolines (pharmacology), Ergolines (therapeutic use), Humans, Levodopa (pharmacology), Levodopa (therapeutic use), Movement Disorders (drug therapy), Movement Disorders (etiology), Nitriles, Nitrophenols (pharmacology), Nitrophenols (therapeutic use), Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson's disease, dopamine agonist, levodopa, motor fluctuations.
- MESH :
- chemical , pharmacology : Apomorphine, Benzophenones, Catechols, Dopamine Agonists, Ergolines, Levodopa, Nitrophenols.
- chemical , therapeutic use : Apomorphine, Benzophenones, Catechols, Dopamine Agonists, Ergolines, Levodopa, Nitrophenols.
- chemical : Catechol O-Methyltransferase Inhibitors, Nitriles.
- complications : Parkinson Disease.
- drug therapy : Movement Disorders, Parkinson Disease.
- etiology : Movement Disorders.
- Humans.
Abstract
Although levodopa remains the most effective drug for the symptomatic treatment of Parkinson's disease (PD), there are significant limitations to its chronic use. Growing preclinical and clinical evidence suggests that the severity of motor fluctuations is influenced both by PD severity and pulsatile stimulation of striatal dopamine receptors. Current management of motor fluctuations is based primarily on strategies to prolong the effects of dopaminergic stimulation. This prolongation is accomplished either through the use of long‐acting dopaminergic drugs or prolonging of the effects of levodopa. During the past decade, the armamentarium of dopamine agonists increased and agents that prolong the plasma half‐life of levodopa became available. Furthermore, recent clinical trials provide evidence‐based approaches to improve the management of motor fluctuations in patients with advanced and early PD. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20461
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001081
- to stream Istex, to step Curation: 001081
- to stream Istex, to step Checkpoint: 002148
- to stream PubMed, to step Corpus: 003080
- to stream PubMed, to step Curation: 003080
- to stream PubMed, to step Checkpoint: 002F73
- to stream Ncbi, to step Merge: 001221
- to stream Ncbi, to step Curation: 001221
- to stream Ncbi, to step Checkpoint: 001221
Links to Exploration step
ISTEX:0F2A6E5F15C1C654BE72E1E19498EEAEABCF3607Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations</title><author><name sortKey="Widnell, Katherine L" sort="Widnell, Katherine L" uniqKey="Widnell K" first="Katherine L." last="Widnell">Katherine L. Widnell</name></author><author><name sortKey="Comella, Cynthia" sort="Comella, Cynthia" uniqKey="Comella C" first="Cynthia" last="Comella">Cynthia Comella</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0F2A6E5F15C1C654BE72E1E19498EEAEABCF3607</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20461</idno><idno type="url">https://api.istex.fr/document/0F2A6E5F15C1C654BE72E1E19498EEAEABCF3607/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001081</idno><idno type="wicri:Area/Istex/Curation">001081</idno><idno type="wicri:Area/Istex/Checkpoint">002148</idno><idno type="wicri:doubleKey">0885-3185:2005:Widnell K:role:of:comt</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15822107</idno><idno type="wicri:Area/PubMed/Corpus">003080</idno><idno type="wicri:Area/PubMed/Curation">003080</idno><idno type="wicri:Area/PubMed/Checkpoint">002F73</idno><idno type="wicri:Area/Ncbi/Merge">001221</idno><idno type="wicri:Area/Ncbi/Curation">001221</idno><idno type="wicri:Area/Ncbi/Checkpoint">001221</idno><idno type="wicri:doubleKey">0885-3185:2005:Widnell K:role:of:comt</idno><idno type="wicri:Area/Main/Merge">004E25</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations</title><author><name sortKey="Widnell, Katherine L" sort="Widnell, Katherine L" uniqKey="Widnell K" first="Katherine L." last="Widnell">Katherine L. Widnell</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Regional Parkinson Center, Aurora Sinai Medical Center, Milwaukee, Wisconsin</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation></author><author><name sortKey="Comella, Cynthia" sort="Comella, Cynthia" uniqKey="Comella C" first="Cynthia" last="Comella">Cynthia Comella</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-05">2005-05</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">S11</biblScope><biblScope unit="supplement">11</biblScope><biblScope unit="page" from="S30">S30</biblScope><biblScope unit="page" to="S37">S37</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">0F2A6E5F15C1C654BE72E1E19498EEAEABCF3607</idno><idno type="DOI">10.1002/mds.20461</idno><idno type="ArticleID">MDS20461</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Apomorphine (pharmacology)</term><term>Apomorphine (therapeutic use)</term><term>Benzophenones (pharmacology)</term><term>Benzophenones (therapeutic use)</term><term>COMT inhibition</term><term>Catechol O-Methyltransferase Inhibitors</term><term>Catechols (pharmacology)</term><term>Catechols (therapeutic use)</term><term>Dopamine Agonists (pharmacology)</term><term>Dopamine Agonists (therapeutic use)</term><term>Ergolines (pharmacology)</term><term>Ergolines (therapeutic use)</term><term>Humans</term><term>Levodopa (pharmacology)</term><term>Levodopa (therapeutic use)</term><term>Movement Disorders (drug therapy)</term><term>Movement Disorders (etiology)</term><term>Nitriles</term><term>Nitrophenols (pharmacology)</term><term>Nitrophenols (therapeutic use)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson's disease</term><term>dopamine agonist</term><term>levodopa</term><term>motor fluctuations</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Apomorphine</term><term>Benzophenones</term><term>Catechols</term><term>Dopamine Agonists</term><term>Ergolines</term><term>Levodopa</term><term>Nitrophenols</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Apomorphine</term><term>Benzophenones</term><term>Catechols</term><term>Dopamine Agonists</term><term>Ergolines</term><term>Levodopa</term><term>Nitrophenols</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Catechol O-Methyltransferase Inhibitors</term><term>Nitriles</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Movement Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Movement Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Although levodopa remains the most effective drug for the symptomatic treatment of Parkinson's disease (PD), there are significant limitations to its chronic use. Growing preclinical and clinical evidence suggests that the severity of motor fluctuations is influenced both by PD severity and pulsatile stimulation of striatal dopamine receptors. Current management of motor fluctuations is based primarily on strategies to prolong the effects of dopaminergic stimulation. This prolongation is accomplished either through the use of long‐acting dopaminergic drugs or prolonging of the effects of levodopa. During the past decade, the armamentarium of dopamine agonists increased and agents that prolong the plasma half‐life of levodopa became available. Furthermore, recent clinical trials provide evidence‐based approaches to improve the management of motor fluctuations in patients with advanced and early PD. © 2005 Movement Disorder Society</div></front></TEI><double doi="10.1002/mds.20461"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations</title><author><name sortKey="Widnell, Katherine L" sort="Widnell, Katherine L" uniqKey="Widnell K" first="Katherine L." last="Widnell">Katherine L. Widnell</name></author><author><name sortKey="Comella, Cynthia" sort="Comella, Cynthia" uniqKey="Comella C" first="Cynthia" last="Comella">Cynthia Comella</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0F2A6E5F15C1C654BE72E1E19498EEAEABCF3607</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20461</idno><idno type="url">https://api.istex.fr/document/0F2A6E5F15C1C654BE72E1E19498EEAEABCF3607/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001081</idno><idno type="wicri:Area/Istex/Curation">001081</idno><idno type="wicri:Area/Istex/Checkpoint">002148</idno><idno type="wicri:doubleKey">0885-3185:2005:Widnell K:role:of:comt</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations</title><author><name sortKey="Widnell, Katherine L" sort="Widnell, Katherine L" uniqKey="Widnell K" first="Katherine L." last="Widnell">Katherine L. Widnell</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Regional Parkinson Center, Aurora Sinai Medical Center, Milwaukee, Wisconsin</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation></author><author><name sortKey="Comella, Cynthia" sort="Comella, Cynthia" uniqKey="Comella C" first="Cynthia" last="Comella">Cynthia Comella</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-05">2005-05</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">S11</biblScope><biblScope unit="supplement">11</biblScope><biblScope unit="page" from="S30">S30</biblScope><biblScope unit="page" to="S37">S37</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">0F2A6E5F15C1C654BE72E1E19498EEAEABCF3607</idno><idno type="DOI">10.1002/mds.20461</idno><idno type="ArticleID">MDS20461</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>COMT inhibition</term><term>Parkinson's disease</term><term>dopamine agonist</term><term>levodopa</term><term>motor fluctuations</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Although levodopa remains the most effective drug for the symptomatic treatment of Parkinson's disease (PD), there are significant limitations to its chronic use. Growing preclinical and clinical evidence suggests that the severity of motor fluctuations is influenced both by PD severity and pulsatile stimulation of striatal dopamine receptors. Current management of motor fluctuations is based primarily on strategies to prolong the effects of dopaminergic stimulation. This prolongation is accomplished either through the use of long‐acting dopaminergic drugs or prolonging of the effects of levodopa. During the past decade, the armamentarium of dopamine agonists increased and agents that prolong the plasma half‐life of levodopa became available. Furthermore, recent clinical trials provide evidence‐based approaches to improve the management of motor fluctuations in patients with advanced and early PD. © 2005 Movement Disorder Society</div></front></TEI></ISTEX><PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.</title><author><name sortKey="Widnell, Katherine L" sort="Widnell, Katherine L" uniqKey="Widnell K" first="Katherine L" last="Widnell">Katherine L. Widnell</name><affiliation wicri:level="2"><nlm:affiliation>Regional Parkinson Center, Aurora Sinai Medical Center, Milwaukee, Wisconsin, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Regional Parkinson Center, Aurora Sinai Medical Center, Milwaukee, Wisconsin</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation></author><author><name sortKey="Comella, Cynthia" sort="Comella, Cynthia" uniqKey="Comella C" first="Cynthia" last="Comella">Cynthia Comella</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="doi">10.1002/mds.20461</idno><idno type="RBID">pubmed:15822107</idno><idno type="pmid">15822107</idno><idno type="wicri:Area/PubMed/Corpus">003080</idno><idno type="wicri:Area/PubMed/Curation">003080</idno><idno type="wicri:Area/PubMed/Checkpoint">002F73</idno><idno type="wicri:Area/Ncbi/Merge">001221</idno><idno type="wicri:Area/Ncbi/Curation">001221</idno><idno type="wicri:Area/Ncbi/Checkpoint">001221</idno><idno type="wicri:doubleKey">0885-3185:2005:Widnell K:role:of:comt</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.</title><author><name sortKey="Widnell, Katherine L" sort="Widnell, Katherine L" uniqKey="Widnell K" first="Katherine L" last="Widnell">Katherine L. Widnell</name><affiliation wicri:level="2"><nlm:affiliation>Regional Parkinson Center, Aurora Sinai Medical Center, Milwaukee, Wisconsin, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Regional Parkinson Center, Aurora Sinai Medical Center, Milwaukee, Wisconsin</wicri:regionArea><placeName><region type="state">Wisconsin</region></placeName></affiliation></author><author><name sortKey="Comella, Cynthia" sort="Comella, Cynthia" uniqKey="Comella C" first="Cynthia" last="Comella">Cynthia Comella</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Apomorphine (pharmacology)</term><term>Apomorphine (therapeutic use)</term><term>Benzophenones (pharmacology)</term><term>Benzophenones (therapeutic use)</term><term>Catechol O-Methyltransferase Inhibitors</term><term>Catechols (pharmacology)</term><term>Catechols (therapeutic use)</term><term>Dopamine Agonists (pharmacology)</term><term>Dopamine Agonists (therapeutic use)</term><term>Ergolines (pharmacology)</term><term>Ergolines (therapeutic use)</term><term>Humans</term><term>Levodopa (pharmacology)</term><term>Levodopa (therapeutic use)</term><term>Movement Disorders (drug therapy)</term><term>Movement Disorders (etiology)</term><term>Nitriles</term><term>Nitrophenols (pharmacology)</term><term>Nitrophenols (therapeutic use)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Apomorphine</term><term>Benzophenones</term><term>Catechols</term><term>Dopamine Agonists</term><term>Ergolines</term><term>Levodopa</term><term>Nitrophenols</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Apomorphine</term><term>Benzophenones</term><term>Catechols</term><term>Dopamine Agonists</term><term>Ergolines</term><term>Levodopa</term><term>Nitrophenols</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Catechol O-Methyltransferase Inhibitors</term><term>Nitriles</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Movement Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Movement Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Although levodopa remains the most effective drug for the symptomatic treatment of Parkinson's disease (PD), there are significant limitations to its chronic use. Growing preclinical and clinical evidence suggests that the severity of motor fluctuations is influenced both by PD severity and pulsatile stimulation of striatal dopamine receptors. Current management of motor fluctuations is based primarily on strategies to prolong the effects of dopaminergic stimulation. This prolongation is accomplished either through the use of long-acting dopaminergic drugs or prolonging of the effects of levodopa. During the past decade, the armamentarium of dopamine agonists increased and agents that prolong the plasma half-life of levodopa became available. Furthermore, recent clinical trials provide evidence-based approaches to improve the management of motor fluctuations in patients with advanced and early PD.</div></front></TEI></PubMed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004E25 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 004E25 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:0F2A6E5F15C1C654BE72E1E19498EEAEABCF3607
|texte= Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations
}}
| This area was generated with Dilib version V0.6.23. |  |